Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activations

BR.28/CONVERT -- Concurrent ONce-daily VErsus twice-daily RadioTherapy: A 2-arm randomized controlled trial of concurrent chemo-radiotherapy comparing twice daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status -- was centrally activated 9 December 2008.

HN.6 -- A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck -- was centrally activated 18 December 2008.